curve guardian glp-1 LY3437943, a novel triple glucagon, GIP, and receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Discontinuation and Reinitiation of Dual-Labeled

This comes as the American College of Cardiology (ACC) released its five top trends in cardiovascular medicine in 2025, including Anti-Obesity Drugs: Cardiovascular Benefit Beyond Weight Loss. The ACC reports that semaglutide and tirzepatide both demonstrate remarkable cardiovascular benefits that extend beyond weight management. Clinical trials show these medications can reduce the risk of major adverse cardiovascular events by up to 20% in patients with obesity and preexisting cardiovascular conditions

Book a phone consultation at your convenience 7 days a week

The protein was aliquoted and stored at 80 C for future use

Some protocols run to week 16

As far as the three MACE components are concerned, the use of GLP-1RA was associated with 13% reduced risk of cardiovascular mortality (HR = 0.87, Fig